Professor Doctorate of Anadolu University, Faculty of Pharmacy, Eskişehir, Turkey.
Mehlika Dilek Altıntop is a researcher specializing in the synthesis of bioactive compounds with therapeutic potential for cancer and metabolic disorders. Her work focuses on designing and evaluating enzyme inhibitors, particularly aldose reductase inhibitors for diabetes treatment. In pharmaceutical chemistry, she investigates new chemical entities with antimicrobial and anticancer activities. Altıntop also explores molecular hybridization to enhance biological activity and is involved in drug development, including the creation of innovative compounds like triazolothiadiazine derivatives. Her research contributes significantly to advancing treatment options and improving therapeutic outcomes.
Profile
Education:
Mehlika Dilek Altıntop’s educational journey began at İkieylül Elementary School, where she completed her primary education from 1991 to 1996. She then attended Eskişehir Anatolian High School for her secondary and high school education from 1996 to 2003. Pursuing higher education, she enrolled at Anadolu University, Faculty of Pharmacy, graduating with her undergraduate degree in 2007. She continued her academic career at Anadolu University, where she completed a Master’s Degree with Thesis in Pharmaceutical Chemistry at the Graduate School of Health Sciences between 2007 and 2009. Subsequently, she earned her Doctoral Degree in Pharmaceutical Chemistry from the same institution, graduating in 2012. Additionally, she possesses an excellent command of English, which complements her academic and professional expertise.
Academic Titles:
Prof. Dr. Mehlika Dilek Altıntop has had a distinguished career at Anadolu University, Faculty of Pharmacy. She began as a Research Assistant from 2010 to 2012, where she gained foundational experience in pharmaceutical research. She then advanced to the role of Research Assistant Doctor from 2012 to 2014, further deepening her expertise. Her career continued to progress as she took on the position of Assistant Professor Doctor from 2014 to 2015, during which she began to establish her reputation in the field. In 2015, she was promoted to Associate Professor Doctor, a role she held until 2020. Since 2020, Prof. Dr. Altıntop has served as a Professor Doctor at Anadolu University, where she continues to contribute significantly to the field of pharmacy through both her research and teaching activities. Her career reflects a consistent trajectory of academic growth and leadership.
Awards:
Prof. Dr. Mehlika Dilek Altıntop has received numerous accolades throughout her distinguished career. In 2007, she was honored with the Anadolu University Faculty of Pharmacy Championship Award and the Graduate Scholarship from The Scientific and Technological Research Council of Turkey. Her exceptional contributions were further recognized with the Anadolu University Science and Technology Encouragement Award and several Article Performance Awards from 2014 to 2018. She achieved the Gold and Platinum Article Performance Awards in 2015 and was named Outstanding Reviewer by the European Journal of Medicinal Chemistry in 2016. In 2019, she received the Turkish Pharmacists’ Association Academy of Pharmacy Encouragement Award. Prof. Altıntop was awarded the Anadolu University Academic Outstanding Success Award in 2020 and 2021 and recognized as the Outstanding Woman Researcher in Pharmaceutical Chemistry at VIWA 2021. Her invention, “Targeted Novel Triazolothiadiazine Derivatives for The Treatment of Lung Cancer,” earned a Silver Medal at ISIF’21. Her top-cited articles in Archiv der Pharmazie and Open Chemistry further highlight her impactful research.
Dr. Mehlika Dilek Altıntop’s research focuses on medicinal chemistry, with a particular emphasis on:
Mehlika Dilek Altıntop’s research is centered on the synthesis and development of bioactive compounds with significant therapeutic potential, particularly for cancer and metabolic disorders. Her work involves designing and evaluating enzyme inhibitors, such as aldose reductase inhibitors, to address conditions like diabetes. In pharmaceutical chemistry, she investigates new chemical entities and their pharmacological effects, including antimicrobial and anticancer properties. A key aspect of her research is molecular hybridization, where she combines different molecular scaffolds to enhance biological activity. Her focus on drug development includes the creation and testing of innovative drugs, exemplified by her work on triazolothiadiazine derivatives and other novel compounds. Altıntop’s contributions aim to advance therapeutic options and improve treatment outcomes across a range of medical conditions.
PUBLICATION TOP NOTES:
- “Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy”
Altıntop, M.D., Ertorun, İ., Akalın Çiftçi, G., Özdemir, A.
European Journal of Medicinal Chemistry, 2024
- “Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents”
Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
ACS Omega, 2024
- “Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents”
Altıntop, M.D., Cantürk, Z., Özdemir, A.
ACS Omega, 2023
- “Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy”
Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
ACS Omega, 2023
- “A new series of hydrazones as small-molecule aldose reductase inhibitors”
Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
Archiv der Pharmazie, 2023
- “A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell lung cancer”
Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
Drug Development Research, 2023
- “Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with Anti-Inflammatory Action”
Altıntop, M.D., Akalın Çiftçi, G., Yılmaz Savaş, N., Alataş, Ö., Özdemir, A.
International Journal of Molecular Sciences, 2023
- “Microwave-assisted synthesis of a series of 4,5-dihydro-1H-pyrazoles endowed with selective COX-1 inhibitory potency”
Altıntop, M.D., Temel, H.E., Özdemir, A.
Journal of the Serbian Chemical Society, 2023
- “Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer”
Altıntop, M.D., Özdemir, A., Temel, H.E., Kaplancıklı, Z.A., Akalın Çiftçi, G.
European Journal of Medicinal Chemistry, 2022